Elite Pharmaceuticals

Elite Pharmaceuticals is a specialty pharmaceutical company with a dual-strategy mission: to generate revenue from a portfolio of niche, controlled-release generic drugs while advancing a proprietary pipeline of abuse-deterrent opioid products. The company leverages its in-house cGMP and DEA-registered manufacturing facility and its core competency in complex oral formulations to create products with higher technical barriers to entry. Its long-term strategy hinges on the successful development and regulatory approval of its ART™ platform, aiming to address the critical public health need for safer pain management therapies.

Abuse-Resistant Technology (ART™), a pharmacological, bead-based platform designed to deter opioid abuse via crushing/snorting, dissolving/injection, and extraction. It features 'One Bead' and 'Two Bead' delivery systems.

In generics, Elite competes with large manufacturers and niche players, relying on formulation expertise. In abuse-deterrent opioids, it faces established products from Collegium, Hikma, and others. Its potential edge lies in its pharmacological ART™ platform and integrated manufacturing, but it is a late entrant in a challenging market.